Veru Inc. Presents Pre-Conference Workshop Session 'Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success With the FDA' at the 4th Annual Obesity & Weight Loss Drug Development Summit in Boston on Tuesday July 14 at 1:30 PM ET, With CEO Mitchell Steiner Following on Wednesday July 15 With 'Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s With Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss' — Veru's Enobosarm-Plus-GLP-1 Program Anchors the Muscle-Preservation Thesis for Weight-Loss Therapy
Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, presented at the 4th Annual Obesity & Weight Loss Drug Development Summit in Boston, Massachusetts on Tuesday July 14, 2026. Gary Barnette, PhD, Chief Scientific Officer, led the pre-conference workshop 'Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success With the FDA' at 1:30 PM ET. On Wednesday July 15 at 4:20 PM ET, Chairman, President and CEO Mitchell Steiner, MD will present 'Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s With Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss.' Veru's lead asset enobosarm is a selective androgen receptor modulator (SARM) in Phase 2b development for muscle-loss prevention in older patients receiving GLP-1 receptor agonists for weight loss. The sarcopenic-obesity thesis directly addresses a widely documented GLP-1 side effect: approximately 25-40% of GLP-1-associated weight loss is lean muscle mass rather than fat, particularly in older patients. Veru's approach pairs the GLP-1 with a SARM to preserve muscle while maintaining fat loss.